Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 6/20 | 0.47 |
| ▸ | CFD | P00746 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774917 | 0.89 | ICMT (0.45) | ICMTCFDCNR1CNR2SERPINE1 | |
| SCHEMBL18555919 | 0.89 | ICMT (0.45) | ICMTCFDCNR1CNR2SERPINE1 | |
| SCHEMBL18555286 | 0.85 | ICMT (0.43) | ICMTCFDCNR1CNR2SERPINE1 | |
| SCHEMBL29546024 | 0.85 | ICMT (0.43) | ICMTCFDCNR1CNR2SERPINE1 | |
| SCHEMBL18555837 | 0.85 | ICMT (0.42) | ICMTCFDCNR1CNR2SERPINE1 | |
| SCHEMBL18591263 | 0.81 | ICMT (0.41) | ICMTCFDCNR1CNR2SERPINE1 | |
| SCHEMBL29841210 | 0.81 | ICMT (0.41) | ICMTCFDCNR1CNR2SERPINE1 | |
| SCHEMBL18591169 | 0.80 | ICMT (0.48) | ICMTCFD | |
| Trifluoroacetic Acid SCHEMBL29841176 | 0.79 | KDM4E (0.43) | ICMTCFDSERPINE1 | |
| SCHEMBL18611187 | 0.79 | ICMT (0.40) | ICMTCFDSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | ICMT 4435/4885CFD 1/4885CNR1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.